This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
WHO Wants Cancer Biosimilars
Will a pilot project to prequalify “generic” biologics improve safe access to medicines?